Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Clinical Trials

GALIP: effect of the GLP1 receptor agonist Lixisenatide in pancreas transplantation

GALIP is a phase 2 safety and efficacy study. When activated, glucagon-like protein 1 (GLP1) receptor stimulates the production and release of insulin from the pancreas. It is hoped that the GLP1 receptor agonist Lixisenatide will improve prognosis in pancreas transplantation.

Susan Dutton and Karan Vadher